Shares of Sun Pharmaceutical Industries Ltd were trading marginally higher during the early trading hours on 19 March after the company announced receiving regulatory approval from the Australian Therapeutic Goods Administration for Winlevi cream indicated for the topical treatment of acne.

The pharma major has received approval for Winlevi cream, which is used for the topical treatment of acne vulgaris in patients who are 12 years of age or older.

The company has received exclusive rights to develop and commercialise Winlevi in the US, Australia, New Zealand, Japan, Russia, and Mexico.

Hellen de Kloet, Business Head, Western Europe, Australia and New Zealand of Sun Pharma, said, “Winlevi is an exciting addition to our expanding dermatology portfolio of innovative medicines in Australia. Winlevi’s novel mechanism of action will be a welcome addition to the physician’s toolkit while treating acne.”

At 3:30 pm, the shares of Sun Pharma shed all its early gains and closed 1.49% lower at Rs 1,547.90 on NSE.